Han XiaoXuan, Li Danni, Zhu Yimin, Schneider-Futschik Elena K
Department of Biochemistry & Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC 3010, Australia.
ACS Pharmacol Transl Sci. 2024 Mar 14;7(4):933-950. doi: 10.1021/acsptsci.3c00362. eCollection 2024 Apr 12.
Cystic fibrosis (CF) is a genetic disorder arising from variations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leading to multiple organ system defects. CFTR tool compounds are molecules that can modify the activity of the CFTR channel. Especially, patients that are currently not able to benefit from approved CFTR modulators, such as patients with rare CFTR variants, benefit from further research in discovering novel tools to modulate CFTR. This Review explores the development and classification of CFTR tool compounds, including CFTR blockers (CFTRinh-172, GlyH-101), potentiators (VRT-532, Genistein), correctors (VRT-325, Corr-4a), and other approved and unapproved modulators, with detailed descriptions and discussions for each compound. The challenges and future directions in targeting rare variants and optimizing drug delivery, and the potential synergistic effects in combination therapies are outlined. CFTR modulation holds promise not only for CF treatment but also for generating CF models that contribute to CF research and potentially treating other diseases such as secretory diarrhea. Therefore, continued research on CFTR tool compounds is critical.
囊性纤维化(CF)是一种由囊性纤维化跨膜传导调节因子(CFTR)基因变异引起的遗传性疾病,会导致多器官系统缺陷。CFTR工具化合物是能够改变CFTR通道活性的分子。特别是,目前无法从已获批的CFTR调节剂中获益的患者,如携带罕见CFTR变异的患者,有望从发现新型CFTR调节工具的进一步研究中受益。本综述探讨了CFTR工具化合物的开发与分类,包括CFTR阻滞剂(CFTRinh-172、GlyH-101)、增强剂(VRT-532、染料木黄酮)、校正剂(VRT-325、Corr-4a)以及其他已获批和未获批的调节剂,并对每种化合物进行了详细描述与讨论。概述了针对罕见变异和优化药物递送方面的挑战与未来方向,以及联合疗法中的潜在协同效应。CFTR调节不仅有望用于CF治疗,还能用于构建有助于CF研究的CF模型,并可能治疗其他疾病,如分泌性腹泻。因此,持续开展CFTR工具化合物的研究至关重要。